



REC'D 20/3/03 01 MAR 2005



INVESTOR IN PEOPLE

#2

REC'D 20 OCT 2003  
WIPO PCT

The Patent Office  
Concept House  
Cardiff Road  
Newport  
South Wales  
NP10 8QQ

I, the undersigned, being an officer duly authorised in accordance with Section 74(1) and (4) of the Deregulation & Contracting Out Act 1994, to sign and issue certificates on behalf of the Comptroller-General, hereby certify that annexed hereto is a true copy of the documents as originally filed in connection with the patent application identified therein.

In accordance with the Patents (Companies Re-registration) Rules 1982, if a company named in this certificate and any accompanying documents has re-registered under the Companies Act 1980 with the same name as that with which it was registered immediately before re-registration save for the substitution as, or inclusion as, the last part of the name of the words "public limited company" or their equivalents in Welsh, references to the name of the company in this certificate and any accompanying documents shall be treated as references to the name with which it is so re-registered.

In accordance with the rules, the words "public limited company" may be replaced by p.l.c., plc, P.L.C. or PLC.

Re-registration under the Companies Act does not constitute a new legal entity but merely subjects the company to certain additional company law rules.

Signed

Dated 19 August 2003


**PRIORITY  
DOCUMENT**

SUBMITTED OR TRANSMITTED IN  
COMPLIANCE WITH RULE 17.1(a) OR (b)

An Executive Agency of the Department of Trade and Industry

**BEST AVAILABLE COPY**

1/77



**Request for grant of a patent**

(See the notes on the back of this form. You can also get an explanatory leaflet from the Patent Office to help you fill in this form)

**The Patent Office**

Cardiff Road  
Newport  
Gwent NP10 8QQ

1.	Your reference	4-32671P1	14SEP02 E748220-2 D00524 740 0 00-0221312.2
2.	Patent application number (The Patent Office will fill in this part)	0221312.2	13 SEP 2002
3.	Full name, address and postcode of the or of each applicant (underline all surnames)	NOVARTIS AG LICHTSTRASSE 35 4056 BASEL SWITZERLAND 07125 487005 SWITZERLAND	
	Patent ADP number (if you know it)		
	If the applicant is a corporate body, give the country/state of its incorporation		
4.	Title of invention	Organic compounds	
5.	Name of your agent (If you have one) "Address for service" in the United Kingdom to which all correspondence should be sent (including the postcode)	Novartis Pharmaceuticals UK Ltd Patents and Trademarks Wimblehurst Road HORSHAM West Sussex RH12 5AB ADP No 0718522002	
	Patents ADP number (if you know it)		
6.	If you are declaring priority from one ore more earlier patent applications, give the country and the date of filing of the or of each of these earlier applications and (if you know it) the or each application number	Country	Priority application number (if you know it)
			Date of filing (day/month/year )
7.	If this application is divided or otherwise derived from an earlier UK application, give the number and the filing date of the earlier application	Number of earlier application	Date of filing (day/month/year)
8.	Is a statement of inventorship and of right to grant of a patent required in support of this request? (Answer 'Yes' if: a) any applicant named in part 3 is not an inventor, or b) there is an inventor who is not named as an applicant, or c) any named applicant is a corporate body. (see note (d))	Yes	

**Patents Form 1/77**

9. Enter the number of sheets for any of the following items you are filing with this form. Do not count copies of the same document

Continuation sheets of this form

Description **31**

Claim(s) **20**

Abstract

Drawing(s) **5** *XS*

10. If you are also filing any of the following, state how many against each item.

Priority documents

Translations of priority documents

Statement of inventorship and right to grant of a patent (*Patents Form 7/77*)

Request for preliminary examination and search (*Patents Form 9/77*)

**ONE** ✓

Request for substantive examination (*Patents Form 10/77*)

Any other documents (*please specify*)

11.

I/We request the grant of a patent on the basis of this application

Signature

Date

*B.A. Yorke & Co*

**B.A. Yorke & Co.**

**13 September 2002**

12. Name and daytime telephone number of person to contact in the United Kingdom

**Mrs. E. Cheetham**  
**020 8560 5847**

**Warning**

*After an application for a patent has been filed, the Comptroller of the Patent Office will consider whether publication or communication of the invention should be prohibited or restricted under Section 22 of the Patents Act 1977. You will be informed if it is necessary to prohibit or restrict your invention in this way. Furthermore, if you live in the United Kingdom, Section 23 of the Patents Act 1977 stops you from applying for a patent abroad without first getting written permission from the Patent Office unless an application has been filed at least 6 weeks beforehand in the United Kingdom for a patent for the same invention and either no direction prohibiting publication or communication has been given, or any such direction has been revoked.*

**Notes**

- If you need help to fill in this form or you have any questions, please contact the Patent Office on 0645 500505.*
- Write your answers in capital letters using black ink or you may type them.*
- If there is not enough space for all the relevant details on any part of this form, please continue on a separate sheet of paper and write "see continuation sheet" in the relevant part(s). Any continuation sheet should be attached to this form.*
- Once you have filled in the form you must remember to sign and date it.*
- For details of the fee and ways to pay please contact the Patent Office.*

**DUPLICATE**

- 1 -

---

**Organic compounds**

---

The invention relates to a new process for the production of epothilone derivatives having not only the 2-methyl-thiazole substituent but, for example, other heteroaryl or aryl substituents or heterocyclic radicals fused to a benzene nucleus and methyl as substituent in 12-position within the epothilone structure, new epothilone derivatives as well as intermediate products for the process and methods for preparing them. Said intermediates are new compounds as such and part of the invention.

The epothilones (16-membered macrolides which were initially isolated from the mycobacterium *Sorangium cellulosum*) represent a class of promising anti-tumor agents, and have been found to be potent against various cancer lines, including breast cancer cell lines.

These agents have the same biological mechanism of action as Taxol, an anti-cancer drug currently used as primary therapy for the treatment of breast cancer and have been reported to be more potent than Taxol.

Potential applications of the epothilones are the treatment of Alzheimer's disease, malaria and diseases caused by gram-negative organisms. In particular, epothilones are suitable for the treatment of proliferative diseases.

The term "proliferative disease" relates especially to solid tumor diseases, liquid tumors, e.g. leukemia, and psoriasis.

The term "solid tumor disease" especially means breast cancer, cancer of the colon and generally the GI tract including gastric cancer, hepatoma; lung cancer, in particular small-cell lung cancer and non-small-cell lung cancer, renal cancer, mesothelioma, glioma, squamous cell carcinoma of the skin, head and neck cancer, genitourinary cancer, e.g. cervical, uterine, ovarian, testicles, prostate or bladder cancer; Hodgkin's disease, carcinoid syndrome or Kaposi's sarcoma.

Epothilone derivatives are already described, e.g., in WO 97/19086. These derivatives are produced starting from natural epothilone A and B.


The total synthesis of epothilone A is described by Schinzer et al in Chem. Eur. J. 1996, 2, No. 11, 1477-1482. Another synthesis of epothilone A and B and derivatives is described by K.C. Nicolaou et al. in Angew. Chem. 1997, 109, 170-172 and Nature, Vol. 387, 1997, 268-272.

In Chem. Commun. 1997, pp. 2343-2344, K.C. Nicolaou et al describe a total synthesis of 26-hydroxy-epothilone B and related compounds involving a selective Wittig olefination reaction, an aldol reaction and macrolactonization as key steps. In more detail the total synthesis of 26-hydroxy-epothilone B and related analogues via a macrolactonization based strategy has been described in Tetrahedron 54 (1998), 7127-7166 by K.C. Nicolaou et al.

Furthermore in WO 98/25029 K.C. Nicolaou et al describe and claim the synthesis of epothilone A, epothilone B, epothilone analogues, libraries of epothilone analogues by using solid phase and solution phase chemistries.

The embodiment and goal of the present invention is to overcome all the drawbacks of the known processes and to provide a more simple and improved process for the preparation of the above mentioned epothilones and epothilone derivatives and salts thereof which is also feasible on industrial scale by shortening the sequence of the synthetic route and which process constitutes a basis of high overall yield in average and provides precursors and final products of high purity.

A synthesis for the preparation of epothilone derivatives of formula 9



(9)

wherein

R1 is methyl, and

R2 has the meaning of an unsubstituted or substituted aryl, an unsubstituted or substituted heteroaryl or an unsubstituted or substituted heterocyclic radical fused to a benzene nucleus, and salts thereof.


The prefix "lower" denotes a radical having up to and including a maximum of 6, especially up to and including a maximum of 4 carbon atoms, the radicals in question being either unbranched or branched with single or multiple branching.

R2 as unsubstituted or substituted aryl is preferably an aromatic radical with 6 to 14 carbon atoms, especially phenyl, naphthyl, fluorenyl or phenanthrenyl, whereby the said radical is unsubstituted or is substituted by one or more substituents, preferably up to three, primarily one or two substituents, especially those selected from amino; lower alkanoylamino, especially acetylamino; halogen, especially fluorine, chlorine or bromine; lower alkyl, especially methyl or also ethyl or propyl; halogen-lower alkyl, especially trifluoromethyl; hydroxy; lower alkoxy, especially methoxy or also ethoxy; phenyl-lower alkoxy, especially benzyloxy; nitro, cyano, C<sub>8</sub>-C<sub>12</sub>-alkoxy, especially n-decyloxy, carbamoyl, lower alkyl-carbamoyl, such as N-methyl- or N-tert-butylcarbamoyl, lower alkanoyl, such as acetyl, phenyloxy, halogen-lower alkyloxy, such as trifluoromethoxy or 1,1,2,2-tetrafluoroethyloxy, lower alkoxycarbonyl, such as ethoxycarbonyl, lower alkylmercapto, such as methylmercapto, halogen-lower alkylmercapto, such as trifluoromethylmercapto, hydroxy-lower alkyl, such as hydroxymethyl or 1-hydroxymethyl, lower alkanesulphonyl, such as methanesulphonyl, halogen-lower alkanesulphonyl, such as trifluoromethanesulphonyl, phenylsulphonyl, dihydroxybora (-B(OH)<sub>2</sub>), 2-methyl-pyrimidin-4-yl, oxazol-5-yl, 2-methyl-1,3-dioxolan-2-yl, 1H-pyrazol-3-yl, 1-methyl-pyrazol-3-yl; and lower alkylenedioxy which is bonded to two adjacent carbon atoms, such as methylenedioxy.


R2 as aryl is especially phenyl.


Halogen is especially fluorine, chlorine, bromine, or iodine, in particular fluorine or chlorine.

R2 being an unsubstituted or substituted heteroaryl is, for example, a radical selected from following structures:




R2 as heterocyclic radical being fused to a benzene nucleus is a radical selected for example from the radicals of formulae






The new synthesis comprises following sequences:

a) reacting a compound of formula 1



(1)


wherein R<sub>2</sub> has the meanings given above and the mesylate group may be replaced by a tosylate group and the like and the tert.butyl-dimethyl silyl protecting group may be replaced by any of the later on listed silylether forming groups, e.g. TES, in all following reaction sequences, with a sultam derived compound of formula 2 as, for example,



(2)



wherein the silyl protecting group TBDMS may be replaced by the TES protecting group and the like, in a selective aldol reaction in the presence of a Lewis acid and addition of a base in an inert solvent at lower temperatures between  $-50$  to  $-100$  °C and thereafter at elevated temperatures between  $-20$  to  $+20$  °C obtaining a compound of formula 3




wherein R<sub>2</sub> has the meanings given above.

The compound of formula 2 as given above may be replaced by a compound of formula 2 wherein the protecting group TBDMS is replaced by any other silyl ether protecting group, e.g. TES as already said above and the compound as such is a new compound.

The compounds of formula 3 are new compounds and are used as intermediates for the next step b) of the process sequence, and


b) the obtained compounds of above formula 3 are reacted at temperatures between  $-70$  and  $+25$  °C in the presence of a silyl-ether forming compound and in the presence of 2,6-lutidine forming compounds of formula 4



wherein R<sub>2</sub> has the meanings given above.

The compounds of formula 4 are new compounds and are used as precursors for the next step c) of the process sequence, and


c) converting an above compound of formula 4 to the carboxylic acid by splitting off the chiral auxiliary group with TBAOH/H<sub>2</sub>O<sub>2</sub> in DME or LiO<sub>2</sub>H in THF/MeOH/H<sub>2</sub>O obtaining a compound of formula 5



wherein R<sub>2</sub> has the meanings given above.

The obtained compounds of formula 5 are new compounds and used as further intermediates for the next step d) of the process sequence, and


d) reacting a compound of above formula 5 with a reducing reagent in an inert solvent cleaving the mesylate group or tosylate group or the like obtaining a compound of formula 6



wherein R<sub>2</sub> has the above given meanings.

The obtained compounds of formula 6 are new compounds and are used as intermediates for the next step e) of the process sequence, and


e) hydrolysing the tri-protected tris-silylether compounds of above formula 6 with a desilylation reagent or an acid in an inert solvent or a mixture thereof, e.g. TASF or HF-pyridine in THF, obtaining a selectively desilylated compound of formula 7



wherein R<sub>2</sub> has the above given meanings.

The compounds of formula 7 are new compounds and are used as precursors for the next step f) of the process sequence, and


f) macrolactonizing obtained compounds of formula 7 according to the conditions described by M. Yamaguchi et al Bull.Chem.Soc.Jpn.,1979, 52 ,1989, obtaining a fully protected epothilone derivative of formula 8



wherein both the silyl protecting groups TBDMS or only one TBDMS silyl protecting group may be replaced by the TES protecting group or the like and R<sub>2</sub> has the above defined meanings.

The obtained compounds of formula 8 are new compounds and are used as precursors for the next step g) of the process sequence, and

g) treating an obtained compound of formula 8 with HF-pyridine in an inert solvent at temperatures between 0° - 30 °C and cleaving both silyl ether protecting groups obtaining epothilone derivatives of formula 9



wherein R1 is methyl and R2 has the above described meanings and optionally converting compounds of formula 9 to a salt with metal cations by conventional methods.

---

The transformation of epothilone B to the corresponding lactam is disclosed in Scheme 21 (pages 31 and 32) and Example 3 of WO99/02514 (pages 48 – 50). The transformation of a compound of formula 9 which is different from epothilone B into the corresponding lactam compound may be achieved analogously.

Inert solvents mentioned in one of the reaction steps a) to g) encompass, but are not limited to methanol, ethanol, propanol, dichloromethane, dichloroethane, DMF, tetrahydrofuran (THF), benzene, toluene, pyridine, ethylacetate, acetone or t-butyl-methyl ether (TBME), hexane or heptane and the like and mixtures thereof.

Organic bases mentioned in one of the reaction steps a) to g) encompass, but are not limited to organic amines such as unsubstituted or hydroxy-substituted mono-, di- or tri-alkyl-amines, especially mono-, di- or tri-lower alkyl-amines, e.g. methylamine, dimethylamine, di-n-propylamine, triethylamine, tri-n-propylamine, tri-n-butylamine and di-isopropylethylamine (iPr<sub>2</sub>Net), as nitrogen heterocycles, ethylene-imine, pyrrolidine, piperidine and morpholine, especially 4-dimethylamino-pyridine (DMAP), pyridine, 2,6-lutidine, 2,6-di-tert-butylpyridine and the like.

Metalo-organic bases are e.g. LDA (lithium diisopropylamine), BuLi, sec.BuLi, KHMDS, LiHMDS, or NaHMDS.

Reducing agents are e.g. DIBAL-H (diisobutylaluminium-hydride), LiAlH<sub>4</sub> (Lithiumaluminium-hydride), lithium triethylboro-hydride and the like.


Silyl-ether forming compounds are for example standard protecting groups used very commonly in organic synthesis and should protect the functional hydroxy groups against unwanted secondary reactions and are besides the tert.butyl-dimethylsilyl group and triethylsilylgroups as given in formula 1 -8 and may be replaced vice versa by TMS, TES, DEIPS, IPDMS, TDS, TIPS, THP (tetrahydropyranyl) or the like or combinations thereof.

---


The term pharmaceutically acceptable metal salts contemplates salts formed with the sodium, potassium, calcium, magnesium, aluminium, iron and zinc ions. The salts are prepared by conventional methods.

Suitable acids for cleaving the bis-trimethylsilanyloxy groups of the compound of formula 4 by hydrolysis are weak organic acids which do not open the epoxide ring of the epothilone structure and are for example dilute acetic acid, propionic acid, glycolic acid, lactic acid, fumaric acid, succinic acid, adipic acid, pimelic acid, suberic acid, azelaic acid, malic acid, tartaric acid, maleic acid, mandelic acid, amino acids, such as glutamic acid or aspartic acid, especially citric acid and the like. Especially may be mentioned HF-pyridine in THF or HF-pyridine in pyridine.

Chiral auxillary groups used for the aldol reaction according to a) of the process sequence are for example the sultam auxillary group or oxazolidinone groups. e.g.



, especially



and other known chiral auxillary groups.

The reaction steps a) to g) of the mentioned process sequence for the preparation of the compounds of formula 9 are carried out in more detail described as follows:

a) Compounds of formula 1 are reacted with a compound of formula 2 for example in the presence of  $\text{TiCl}_4$  and Hünig base ( $\text{iPr}_2\text{NET}$ ) in dichloromethane at a temperature of  $-78^\circ\text{C}$  and thereafter at a temperature of  $0^\circ\text{C}$  obtaining new compounds of formula 3.

b) The obtained compounds of formula 3 are reacted with TBDMSOTf as a silyl-ether forming compound in the presence of 2,6-lutidine at temperatures between  $-20^\circ$  and  $25^\circ\text{C}$ , especially at a temperature of  $-10^\circ\text{C}$  in dichloromethane as inert solvent forming compounds of formula 4.

c) The obtained compounds of formula 4 are converted to the carboxylic acid by splitting off the sultam auxiliary group with TBAOH/H<sub>2</sub>O<sub>2</sub> in DME or LiO<sub>2</sub>H in THF/MeOH/H<sub>2</sub>O obtaining a compound of formula 5.

---

d) The obtained compounds of formula 5 are reacted with LiBHET<sub>3</sub> as reducing reagent in THF as inert solvent for cleaving the mesylate or tosylate group or the like obtaining a compound of formula 6.

e) The obtained compounds of formula 6 are hydrolysed with a desilylation reagent, especially with TASF or an organic acid, especially HF-pyridine in an inert solvent, e.g. pyridine or THF, obtaining compounds of formula 7.

f) The obtained compounds of formula 7 are macrolactonized according to Yamaguchi et al, e.g. treating the hydroxy acid with Et<sub>3</sub>N and 2,4,6-trichlorobenzoyl chloride at lower temperature, e.g. 0 °C and thereafter the reaction mixture is added to a solution of 4-DMAP in toluene and the temperature raised to ca. 75 °C obtaining compounds of formula 8.

g) The obtained protected epothilone derivatives of formula 8 are treated with HF-pyridine in pyridine as inert solvent and after cleavage of both silyl ether protecting groups (TBDMS) epothilone derivatives of formula 9 are obtained, wherein R<sub>1</sub> is methyl and R<sub>2</sub> has the above described meanings and optionally converting compounds of formula 9 wherein R<sub>1</sub> and R<sub>2</sub> have the defined meanings under formula 9 to a salt with metal cations by conventional methods.


The used starting compounds for the process sequence of formula 1 wherein R<sub>2</sub> has the meaning of an unsubstituted or substituted aryl, an unsubstituted or substituted heteroaryl or an unsubstituted or substituted heterocyclic radical fused to a benzene nucleus are used as key-intermediates for the preparation of epothilone derivatives of formula 9 are new and are prepared by following process sequence comprising steps a) - g), as given thereafter.

The detailed meanings of R<sub>2</sub> have been defined under formula 9.

The new developed synthesis comprises following sequences:


---

a) reacting a tert.butyl-1-(S)-6-iodo-2-methyl-hexyloxy-dimethyl-silane of formula X



(X)


with PPH<sub>3</sub> at temperatures between 50 ° - 150 °C, more precisely at a temperature 100° C and thereafter with KHMDS in an inert solvent, especially in THF at 0°C and thereafter cooling the reaction mixture to a temperature between -50 ° to -100 °C, and treating with CH<sub>3</sub>CO<sub>2</sub>Cl more precisely at a temperature of -78 °C obtaining a compound of formula XI



(XI)

and,


b) reacting the obtained compound of formula XI with a compound of formula XII




(XII)

in an inert solvent, e.g. in toluene at temperatures between 20° to 60 °C, more precisely at a temperature of 40 °C obtaining a compound of formula XIII






c) reducing a compound of formula (XIII) with a reducing agent, especially with DIBALH, in an inert solvent, e.g. toluene at temperatures between  $-50^{\circ}$  to  $-100^{\circ}$  °C, more precisely at a temperature of  $-78^{\circ}$  °C and thereafter elevating the temperature to  $0^{\circ}$  °C obtaining a compound of formula XIV



(the drawing of formula XIV and the following compounds thereafter have been simplified),

R<sub>2</sub> has the above meanings, and


d) using the conditions under Sharpless [(+)-diethyl-L-tartrate, Ti(OPr)<sub>4</sub>, t-BuOOH] for epoxidation of a compound of formula XIV obtaining a compound of formula XV



wherein the PGs (the protecting groups TBDMS) may be replaced by other protecting groups, especially by TES and the like), and R<sub>2</sub> has the above given meanings under formula 9.

The obtained compound of formula XV is a new compound and is used as precursor for the next step e) of the process sequence, and


e) introducing the mesylate group into a compound of formula XV by adding mesylate chloride (the mesylate group may be replaced by a corresponding tosylate group or the like) in the presence of triethylamine (Et<sub>3</sub>N) in an inert solvent, e.g. dichloromethane obtaining a compound of formula XVI



wherein R<sub>2</sub> has the above given meaning.

The obtained compound of formula XVI is a new compound and is used as intermediate for the next step f), and

f) treating the obtained compound of formula XVI with an organic acid in an inert solvent, more precisely with pyridinium p-toluenesulfonate or camphor sulfonic acid in absolute ethanol, hydrolysing the one TBDMS protecting group and obtaining a compound of formula XVII



wherein R2 has the above given meanings, and

---

g) oxidizing by using the Swern-oxidation method, e.g. oxidizing the alcoholic group by the promotion of oxalyl chloride and activation of dimethyl sulfoxide, passing the alkoxysulfonium salts and after addition of a base and intramolecularly rearrangement obtaining a keto compound of formula 1 used in the previous inventive process sequence as starting compound.

As mentioned above in the first reaction sequence silyl-ether forming compounds are for example standard protecting groups used very commonly in organic synthesis and should protect the functional hydroxy groups against unwanted secondary reactions and are besides the tert.butyl-dimethylsilyl group and triethylsilyl groups as given in formula 1 -8 and may be replaced vice versa by TMS, TES, DEIPS, IPDMS, TDS, TIPS, THP (tetrahydropyranyl) or the like or combinations thereof.

The inventive process sequence for producing epothilone derivatives of formula 9 shows many advantages in comparison with other known and published synthesis:

- The early introduction of the epoxide avoids surprisingly a problematic epoxidation step at late intermediates within the synthesis sequence,
  - A remarkable stabilization effect was detected for the mesylate and tosylate epoxides. Many steps can be carried out in the presence of these functional groups.
  - High yielding and highly diastereoselective titanium enolate aldol reaction between the  $\alpha$ -branched aldehyde and the ethylketone key fragments could be achieved.
  - The aldol reaction tolerates surprisingly the presence of the mesylate and tosylate epoxide.
  - The aldol reaction allows a highly convergent synthesis of epothilone derivatives.
  - The aldol reaction allows surprisingly to make use of the chiral sultam auxiliary as carboxylate protecting group and therefore avoids additional time consuming reduction and oxidation steps prior to the final macrolactonisation step.
  - The inventive process sequence is a shorter synthetic route than any other published synthetic routes known in literature, furthermore a higher overall yield could be detected.
- All in all the summarized advantages underline the inventive step of mentioned process sequence.
-

A second aspect of the present invention are the novel intermediates, which are prepared according to the reaction described and are useful for the preparation of compounds of formula 9.

The epothilone derivatives of formula 9 for medical treatment may be administered by every known route and may be selected from the group consisting of the intravenous route, the intraarterial route, the intracutaneous route, the subcutaneous route, the oral route, the buccal route, the intramuscular route, the anal route, the transdermal route, the intradermal route, the intratechal route and the like.

Also sustained release formulations may be performed involving biodegradable microspheres, such as microspheres comprising polyacrylic acid, polyglycolic acid or mixtures of these.

The compounds of formula 9 of the invention can be used alone or in combination with other pharmaceutically active substances, e.g. with other chemotherapeutics such as classical cytostatics. In the case of combinations with an other chemotherapeutic, a fixed combination of two or more components (e.g. kit of parts) are prepared as already known to a person of skill in the art, and the compound of the present invention and any other chemo-therapeutic are administered at an interval that allows common, additional or preferably synergistic effect for tumor treatment.

The following non limiting examples illustrate the inventor's preferred method for preparing the claimed compounds of the invention, which should not be construed as limiting the scope of this invention.

Example 1Compound X

(see also Fig. 1)

**6-Benzyloxy-hexanoic acid (II) (*Can. J. Chem.* 1992, 70, 1427)**

To a solution of 102.2 g (0.90 mol) of 6-caprolactone in 1.5 l of toluene was added 250.6 g (4.48 mol) of KOH and 113.3 ml (0.98 mol) of benzylchloride. The reaction mixture was stirred at reflux temperature for 20 h. The reaction was quenched with 1.7 l of water at room temperature. The aqueous layer was separated and the toluene layer was extracted with 200 ml of water. The combined aqueous phases were treated with 300 ml of HCl (conc.) at 12 °C to acidify the solution to pH 1.0. After extraction with 1.1 l of isopropyl acetate in two portions the combined organic extracts were washed with 300 ml of brine and dried over MgSO<sub>4</sub>. Concentration under reduced pressure afforded 151.2 g (76 %) of the acid II as a yellowish oil.  $R_f = 0.35$  (SiO<sub>2</sub>, 95:5 CH<sub>2</sub>Cl<sub>2</sub>-CH<sub>3</sub>OH).

**6-Benzyloxy-hexanoyl chloride (III)**

The crude acid II (110 g, 0.50 mol) was dissolved in 320 ml of toluene. To the solution was added 140 µl of DMF followed by the addition of 56.7 ml (0.66 mol) of oxalylchloride. The reaction mixture was stirred at room temperature over night and concentrated *in vacuo* to afford 126 g of the acid chloride III which was directly used in the next step.

**(S)-4-Benzyl-3-(6-benzyloxy-hexanoyl)-oxazolidin-2-one (V)**

A solution of 87.7 g (0.50 mol) of (S)-4-benzyl-2-oxazolidininone IV was dissolved in 1.4 l of THF and cooled to -78 °C. Hexyllithium (2.5 M in hexanes) (178 ml, 0.45 mol) was added followed by slow addition of a solution of acid chloride III (126 g, 0.50 mol) in 100 ml of THF. After stirring at -78 °C for one additional hour, the resulting solution was allowed to warm to 0 °C. Saturated aqueous ammonium chloride solution (400 ml) was added to quench the reaction. The layers were separated and the organic layer was washed with additional 100 ml of saturated ammonium chloride solution. The THF layer was washed twice with 200 ml of 1 M NaOH and with 500 ml of brine, dried over MgSO<sub>4</sub> and concentrated. The crude product (162.4 g) was purified by flash chromatography (200 g of SiO<sub>2</sub>, heptane/TBME = 80:20 – 60:

20) to yield 110.1 g (58 % over two steps) of the amide V.  $R_f = 0.41$  ( $\text{SiO}_2$ , 1:1 hexanes-TBME).

(S)-4-Benzyl-3-[(S)-6-benzyloxy-2-methyl-hexanoyl]-oxazolidin-2-one (VI)

A THF (200ml) solution of the amide V (120.1 g, 0.32 mol) was added to 372 ml (0.37 mol) of NaHMDS (1.0M in THF) in 380 ml of THF at  $-78^\circ\text{C}$  followed by the addition of a  $\text{CH}_3\text{I}$  (78.4 ml, 1.26 mol) solution in 70 ml of THF. The reaction mixture was stirred for 2 h at  $-78^\circ\text{C}$ . Aqueous saturated ammonium chloride (670 ml) was added to quench the reaction. The layers were separated and the aqueous phase was extracted with 200 ml of TBME. The combined organic layers were washed twice with 250 ml of brine, dried over  $\text{MgSO}_4$  and concentrated *in vacuo*. The product VI (123.9 g) was obtained in 87 % *de* and was directly used in the next step.  $R_f = 0.50$  ( $\text{SiO}_2$ , 1:1 heptane-TBME);

(S)-6-Benzyloxy-2-methyl-hexan-1-ol (VII)

To a suspension of 13.2 g (0.35 mol) of  $\text{LiAlH}_4$  in 380 ml of THF was added a solution of amide VI in 250 ml of THF at  $0^\circ\text{C}$ . The mixture was stirred for 2 h at  $0^\circ\text{C}$  and quenched with 14 ml of  $\text{H}_2\text{O}$ , 14 ml of 15 % NaOH and 25 ml of  $\text{H}_2\text{O}$ . The precipitated aluminum salts were removed by filtration. After concentration of the filtrate, the crude product was purified by silica gel filtration (570 g of  $\text{SiO}_2$ , toluene/EtOAc = 90 : 10, 3 l and toluene/EtOAc = 80 : 20 1 l). The product VII was obtained as a colorless oil (54.5 g, 81 % over two steps).  $R_f = 0.24$  ( $\text{SiO}_2$ , 1:1 heptane-TBME); HPLC: 87% *de* (Chiralcel OD, *n*-hexane/*i*-PrOH = 95:5, 1.0 ml/min,  $30^\circ\text{C}$ )  $t_R = 10.07$  min.

[(S)-6-Benzyloxy-2-methyl-hexyloxy]-*tert*-butyl-dimethyl-silane (VIII)

The alcohol VII (54.4 g, 0.25 mol) was dissolved in 100 ml of DMF and treated with 33.3 g (0.49 mol) of imidazole followed by the slow addition of a solution of 55.4 g (0.37 mol) of *tert*-butyl-dimethylsilylchloride in 100 ml of DMF at  $0^\circ\text{C}$ . The mixture was stirred for 2 hours at  $20^\circ\text{C}$ , then poured onto 240 ml of ice cold 0.1 N HCl and extracted with 300 ml of heptane. The organic layer was washed with additional 100 ml of 0.1 N HCl, 200 ml of saturated aqueous  $\text{NaHCO}_3$ , 200 ml of brine, dried over  $\text{MgSO}_4$  and concentrated *in vacuo*. The crude product (81.5 g) was purified by filtration (670 g of  $\text{SiO}_2$ , toluene) to afford 64.8 g (79 %) of a colorless oil.  $R_f = 0.64$  ( $\text{SiO}_2$ , 1:1 heptane-TBME).

(S)-6-(*tert*-Butyl-dimethyl-silanyloxy)-5-methyl-hexan-1-ol (IX)

A solution of 64.0 g (0.19 mol) of the benzylether VIII in 500 ml of THF was hydrogenated (3.5 bar) over 7.0 g of 20 % Pd(OH)<sub>2</sub>/C for 30 min at ambient temperature. The catalyst was removed by filtration and the filtrate was concentrated to afford alcohol IX as colorless oil (46.9 g, 100 %).  $R_f = 0.33$  (SiO<sub>2</sub>, 1:1 heptane-TBME).

*tert*-Butyl-[(*S*)-6-iodo-2-methyl-hexyloxy]-dimethyl-silane (X)

Triphenylphosphine (23.91 g, 91.16 mmol) and imidazole (12.45 g, 182.9 mmol) were added to a solution of 15 g (60.9 mmol) of alcohol IX in 390 ml of acetonitrile/toluene (1:5) at room temperature. The mixture was cooled to 0 °C and 23.13 g (91.13 mmol) of iodine was added in 4 portions over a period of 10 min. The heterogenous solution was stirred for 90 min. Aqueous sodium bisulfite (4 %, 300 ml) and 100 ml of toluene were added. The aqueous layer was separated and re-extracted with toluene (100 ml). The combined toluene layers were filtered over silica gel and concentrated *in vacuo*. To the residue was added heptane (225 ml). The resulting suspension was stirred for 10 min. and stored at 4 °C for 12 h. Filtration and concentration of the filtrate afforded 21.05 g (97 %) of the iodide X as a pale yellowish oil.  $R_f = 0.66$  (SiO<sub>2</sub>, 7:3 heptane-AcOEt).

Example 2

Aldehyde 1 with TBDMS protecting groups

(see also Fig. 2)

(*S*)-7-(*tert*-Butyl-dimethyl-silanyloxy)-6-methyl-2-(triphenylphosphanylidene)-heptanoic acid methyl ester (XI)

Under argon and at room temperature, iodide X (15.46 g, 43.4 mmol) and triphenylphosphine (12.52 g, 45.75 mmol) were added to toluene (8 ml). The resulting mixture was heated at 100 °C for 3 h. Then, toluene was removed under reduced pressure. THF (400 mL) was added to the residue (29.67 g) and the solution was cooled to 0 °C and subsequently treated with a potassium bis(trimethylsilyl)amide solution in toluene (0.5 M, 174 ml, 86.8 mmol). The resulting orange suspension was stirred for 1 h at 0 °C and then cooled down to -75 °C. Methyl chloroformate (3.72 ml, 48.2 mmol) was added. After stirring for 1 h at -75 °C the yellowish reaction mixture was allowed to warm-up to -40 °C. NaHCO<sub>3</sub> (300 ml) was added followed by EtOAc (300 ml) and water (150 ml). The layers were separated and the aqueous phase was extracted with EtOAc (150 ml). The combined organic layers were washed with a saturated aqueous solution of NaCl (2 x 200 ml), dried over MgSO<sub>4</sub> and

concentrated *in vacuo*. The crude product XI (27.02 g) obtained as a viscous orange oil was directly used in the next step.

(2*E*,6*E*)-(S)-5-(*tert*-Butyl-dimethyl-silanyloxy)-2-[(S)-5-(*tert*-butyl-dimethyl-silanyloxy)-4-methyl-pentyl]-6-methyl-7-(2-methyl-thiazol-4-yl)-hepta-2,6-dienoic acid methyl ester (XIII)  
A solution of ylide (XI) (27 g) in toluene (200 ml) at ambient temperature under argon was treated with solution of aldehyde (XII) (12.7 g, 39.0 mmol) in toluene (80 ml). The resulting mixture was stirred at 70 °C for 5 h. The solvent was removed under reduced pressure. The remaining solid residue (37.8 g) was taken in 370 ml of heptane and stirred successively at 40 °C for 30 min, at room temperature for 2h and 30 min and finally at 0°C for 30 min.. The resulting suspension was filtered and the filtercake was washed with heptane (2 x 60 ml). The filtrates were collected and concentrated *in vacuo* to give 24.85 g of the Wittig product XIII as a yellowish oil which was used for the next step without further purification.  $R_f = 0.59$  (SiO<sub>2</sub>, 1:1 heptane-AcOEt); <sup>1</sup>H-NMR (DMSO-d<sub>6</sub>, 300 MHz, 300 K)  $\delta$  6.90 (s, 1H, C<sub>5</sub>-H), 6.77 (t,  $J = 7.5$  Hz, 1H, C<sub>3</sub>-H), 6.47 (s, 1H, C<sub>7</sub>-H), 4.20 (dd,  $J = 7.2, 5.4$  Hz, 1H, C<sub>5</sub>-H), 3.69 (s, 3H, CO<sub>2</sub>CH<sub>3</sub>), 3.40 (dd,  $J = 9.9, 5.7$  Hz, 1H, C<sub>5</sub>-H<sub>a</sub>), 3.31 (dd,  $J = 9.9, 6.6$  Hz, 1H, C<sub>5</sub>-H<sub>b</sub>), 2.68 (s, 3H, C<sub>2</sub>-CH<sub>3</sub>), 2.44–2.36 and 2.28–2.21 (two m, 4H, C<sub>4</sub>-H<sub>2</sub> and C<sub>1</sub>-H<sub>2</sub>), 2.00 (s, 3H, C<sub>6</sub>-CH<sub>3</sub>), 1.30–1.15 (two m, 4H, C<sub>2</sub>-H<sub>2</sub>, C<sub>3</sub>-H<sub>a</sub> and C<sub>4</sub>-H), 1.06–0.99 (m, 1 H, C<sub>3</sub>-H<sub>b</sub>), 0.86 (s, 9 H, SiC(CH<sub>3</sub>)<sub>3</sub>), 0.85 (s, 9 H, SiC(CH<sub>3</sub>)<sub>3</sub>), 0.83 (d,  $J = 6.6$ , 3H, C<sub>5</sub>-CH<sub>3</sub>), 0.05 (s, 3 H, SiCH<sub>3</sub>), 0.01 (s, 6 H, two SiCH<sub>3</sub>), –0.01 (s, 3 H, SiCH<sub>3</sub>).

(2*E*,6*E*)-(S)-5-(*tert*-Butyl-dimethyl-silanyloxy)-2-[(S)-5-(*tert*-butyl-dimethyl-silanyloxy)-4-methyl-pentyl]-6-methyl-7-(2-methyl-thiazol-4-yl)-hepta-2,6-dien-1-ol (XIV)

To 13.9 g (23 mmol) of allylic ester XIII in 500 ml of THF at –78 °C was added over 10 min 47 ml (70 mmol) of DIBALH (1.5 M in toluene). The reaction mixture was successively stirred at –78 °C for 3 h, allowed to warm to 0 °C within 30 min. and further stirred at 0 °C for 30 min. before being quenched by the addition of 50 ml of aqueous 0.1N HCl. The layers were separated and the aqueous layer was washed with TBME (2 x 50 ml). The combined organic extracts were washed with aqueous saturated NaHCO<sub>3</sub> (2 x 50 ml) and brine (50 ml), dried over MgSO<sub>4</sub> and concentrated *in vacuo*. The crude product was purified by flash-chromatography (SiO<sub>2</sub>, 5:1 heptane/EtOAc) to afford 10.0 g (76 %) of allylic alcohol XIV as a pale yellowish oil.  $R_f = 0.16$  (SiO<sub>2</sub>, 3:1 heptane-AcOEt).



{(2*S*,3*S*)-3-[(*E*)-(*S*)-2-(*tert*-Butyl-dimethyl-silanyloxy)-3-methyl-4-(2-methyl-thiazol-4-yl)-but-3-enyl]-2-[(*S*)-5-(*tert*-butyl-dimethyl-silanyloxy)-4-methyl-pentyl]-oxiranyl]-methanol (XV)

The allylic alcohol (XIV) (3.00 g, 5.28 mmol) was dissolved in 51 ml of CH<sub>2</sub>Cl<sub>2</sub>. A 0.59 M solution of (+)-diethyl-L-tartrate (4.48 ml, 2.64 mmol) in CH<sub>2</sub>Cl<sub>2</sub> was added at -30 °C followed by a 0.34 M solution of titanium(IV) isopropoxide (6.21 ml, 2.11 mmol) in CH<sub>2</sub>Cl<sub>2</sub>. The mixture was stirred for 30 min at -30 °C. Then 2.11 ml (16.6 mmol) of *tert*-butyl-hydroperoxide (5.5 M in decane) was added over 5 min. The reaction mixture was stirred at -30 °C for 24 h. Aqueous NaHSO<sub>3</sub> (4 %, 50 ml) was then added. The layers were separated and the aqueous layer was extracted with ethyl acetate (2 x 50 ml). The combined organic extracts were washed with 50 ml of brine and dried over MgSO<sub>4</sub>. After concentration *in vacuo*, 3.11 g of crude epoxy alcohol XV was obtained as a pale yellowish oil which was used for the next step without further purification *R*<sub>f</sub> = 0.22 (SiO<sub>2</sub>, 2:1 heptane-AcOEt); MS (ES+) *m/z* (%) 606 (100, [M + Na]<sup>+</sup>), 584 (13, [M + H]<sup>+</sup>).

Methanesulfonic acid (2*S*,3*S*)-3-[(*E*)-(*S*)-2-(*tert*-butyl-dimethyl-silanyloxy)-3-methyl-4-(2-methyl-thiazol-4-yl)-but-3-enyl]-2-[(*S*)-5-(*tert*-butyl-dimethyl-silanyloxy)-4-methyl-pentyl]-oxiranylmethyl ester (XVI)

To a solution of crude epoxyalcohol (XV) (3.11 g, 5.3 mmol) in CH<sub>2</sub>Cl<sub>2</sub> (40 mL) at 0 °C, were added 2.74 mL (16.0 mmol) of *N*-ethyldiisopropylamine. The resulting mixture was stirred 15 min. at 0°C. Thereupon, methanesulfonyl chloride was added dropwise (0.75 ml, 8.0 mmol). After stirring for 1 h at 0°C, the reaction solution was quenched with 40 mL of H<sub>2</sub>O and 40 mL of TBME. The layers were separated and the aqueous layer was extracted with TBME (40 ml). The organic extracts were washed with HCl (0.1N) (40 ml), saturated aqueous NaHCO<sub>3</sub> (2 x 40 ml) and brine (40 ml) and dried over MgSO<sub>4</sub>. Concentration *in vacuo* provided 3.79 g of crude mesylate XVI which was used for the next step without further purification. Purification. *R*<sub>f</sub> = 0.27 (SiO<sub>2</sub>, 2:1 heptane-AcOEt); HRMS *m/z* 684.3222 ([M + Na]<sup>+</sup>, C<sub>31</sub>H<sub>59</sub>NO<sub>6</sub>S<sub>2</sub>Si<sub>2</sub> requires 684.3220).

Methanesulfonic acid (2*S*,3*S*)-3-[(*E*)-(*S*)-2-(*tert*-butyl-dimethyl-silanyloxy)-3-methyl-4-(2-methyl-thiazol-4-yl)-but-3-enyl]-2-[(*S*)-5-hydroxy-4-methyl-pentyl]-oxiranylmethyl ester (XVII)  
The crude TBDMS ether XVI (3.79 g, 5.7 mmol) was dissolved in a mixture of CH<sub>2</sub>Cl<sub>2</sub> and CH<sub>3</sub>OH (1:1 v/v) (140 ml) and treated at 0 °C with 1.33 g (5.73 mmol) of 10-camphorsulfonic acid. The reaction mixture was stirred for 1 h at 0 °C. After completion of the deprotection 20 ml of saturated aqueous NaHCO<sub>3</sub> were added along with 20 ml of TBME. The layers were

separated and the aqueous layer was extracted with TBME (2 x 20 mL). The combined organic layers were washed with saturated aqueous NaHCO<sub>3</sub> (2 x 20 ml), brine (20 ml), dried over MgSO<sub>4</sub> and concentrated under reduced pressure. The crude product XVII (3.11 g) obtained as a yellowish oil was used for the next step without further purification.  $R_f$  = 0.28 (SiO<sub>2</sub>, 1:1 heptane-AcOEt).

Methanesulfonic acid (2*S*,3*S*)-3-[(*E*)-(*S*)-2-(*tert*-butyl-dimethyl-silanyloxy)-3-methyl-4-(2-methyl-thiazol-4-yl)-but-3-enyl]-2-[(*S*)-4-methyl-5-oxo-pentyl]-oxiranylmethyl ester (1)

A solution of the alcohol XVII (3.11 g, 5.7 mmol) in CH<sub>2</sub>Cl<sub>2</sub> (15 ml) at 0 °C was treated sequentially with triethylamine (10 ml), DMSO (6 ml) and a solution of SO<sub>3</sub>·pyridine (3.61 g, 22.7 mmol) in DMSO (40 ml) which was added over 5 min. After stirring for 1 h at 0 °C, the reaction mixture was quenched with aqueous NaHSO<sub>4</sub> (10%, 20 ml) and diluted with TBME (20 ml). The layers were separated and the aqueous layer was extracted with TBME (2 x 20 mL). The combined organic layers were washed with saturated aqueous NaHCO<sub>3</sub> (2 x 20 ml), brine (20 ml), dried over MgSO<sub>4</sub> and concentrated under reduced pressure. The residue was purified by flash chromatography (SiO<sub>2</sub>, 3:1 heptane/EtOAc). The aldehyde 1 was obtained as a pale yellowish oil (2.20 g, 76% yield over four steps based on XIV).  $R_f$  = 0.39 (SiO<sub>2</sub>, 1:1 heptane-AcOEt).

### Example 3

#### Aldehyde XVI' with TBDMS protecting groups

(see also Fig. 3)

4-[(*E*)-(*S*)-3-(*tert*-Butyl-dimethyl-silanyloxy)-4-[(2*S*,3*R*)-3-[(*S*)-5-(*tert*-butyl-dimethyl-silanyloxy)-4-methyl-pentyl]-3-iodomethyl-oxiranyl]-2-methyl-but-1-enyl]-2-methyl-thiazole (XVI')

A solution of epoxy-alcohol XV' (50 mg, 86 µmol) triphenylphosphine (34 mg, 0.13 mmol), (50 mg, 86 (34 mg, 0.13 mmol) and imidazole (18 mg, 0.26 mmol) in 5:1 v/v toluene/acetonitrile (2.4 ml) at room temperature under argon was treated with iodine (33 mg, 0.13 mmol) in one portion. After 30 min stirring, the reaction was judged complete (TLC) and was worked-up. The reaction mixture was poured onto aqueous saturated NaHSO<sub>4</sub> (5 ml). The layers were separated and the aqueous layer was extracted with toluene (2 x 2 ml). The combined organic layers were washed with 1N HCl (5 ml), aqueous saturated NaHCO<sub>3</sub> (5 ml) and brine (5 ml), dried over MgSO<sub>4</sub> and concentrated *in vacuo*. The residue was

suspended in heptane and the insoluble triphenylphosphine oxide was removed by filtration. The crude iodide XVI' was obtained as a pale yellowish oil (65 mg) which did not require further purification.

#### Example 4

##### Compound 2

(see also Fig. 4)

#### **1-(10,10-Dimethyl-3,3-dioxo-6-thia-4-aza-tricyclo[5.2.1.0]dec-4-yl)-3-hydroxy-4,4-dimethyl-heptane-1,5-dione (11)**

Under argon and in a teflon flask, The TBDMS ether (10) (9.21g, 18.43 mmol) was mixed with HF-pyridine complex (26.3 ml, 921 mmol) at ambient temperature. The resulting reaction mixture was stirred for 2 h and then quenched by adding it to a stirred aqueous solution of NaHCO<sub>3</sub> (78g in 500 ml of water) along with 200 ml of TBME. The layers were separated and the organic layer was washed with brine (2 x 200 ml), dried over MgSO<sub>4</sub> and concentrated *in vacuo* to give 6.80 g of crude product which did not require any further purification.

#### **1-(10,10-Dimethyl-3,3-dioxo-6-thia-4-aza-tricyclo[5.2.1.0]dec-4-yl)-4,4-dimethyl-3-triethylsilyloxy-heptane-1,5-dione (2)**

To a solution of crude alcohol (11) (6.80 g, 17.6 mmol) in CH<sub>2</sub>Cl<sub>2</sub> (90 ml) at 0°C, 2,6-lutidine (6.14 ml, 52.9 mmol) was added followed by triethylsilyl trifluoromethanesulfonate (7.98 ml, 35.3 mmol). The resulting solution was stirred at 0°C for 30 min. The reaction was carefully quenched by adding 140 ml of 1N HCl along with 150 ml of TBME. The layers were separated and the organic layer was washed successively with 100 ml of saturated aqueous NaHCO<sub>3</sub> and 100 ml of brine, dried over MgSO<sub>4</sub> and concentrated *in vacuo*. Purification of the crude product by chromatography (SiO<sub>2</sub>, 4:6 hexanes/AcOEt), afforded 8.3 g of pure TES-ether 2. (90 % over two steps). *R*<sub>f</sub> = 0.62 (SiO<sub>2</sub>, 1:1 heptane-AcOEt); <sup>1</sup>H-NMR (DMSO-d<sub>6</sub>, 400 MHz, 300 K) δ 4.55 (t, *J* = 5.2 Hz, 1H, C<sub>3</sub>-H), 3.86 (d, *J* = 14.3 Hz, 1H, C<sub>8</sub>-H<sub>a</sub>), 3.83 (t, *J* = 6.1 Hz, 1H, C<sub>1</sub>-H), 3.66 (d, *J* = 14.2 Hz, 1H, C<sub>8</sub>-H<sub>b</sub>), 2.84 (dd, *J* = 17.4, 4.6 Hz, 1H, C<sub>2</sub>-H<sub>a</sub>), 2.54 (m, 3H, C<sub>2</sub>-H<sub>b</sub> and C<sub>7</sub>-H<sub>2</sub>, partially obscured by DMSO), 2.00–1.92 and 1.87–1.73 (2 m, 6H, C<sub>2</sub>-H<sub>2</sub>, C<sub>3</sub>-H and C<sub>5</sub>-H<sub>2</sub>), 1.48–1.20 and 1.34–1.24 (2 m, 2H, C<sub>4</sub>-H<sub>2</sub>), 1.10 (s, 3H, C<sub>4</sub>-CH<sub>3</sub>), 1.07 (s, 3H, C<sub>4</sub>-CH<sub>3</sub>), 0.98 (s, 3H, C<sub>9</sub>-CH<sub>3</sub>), 0.95 (s, 3H, C<sub>9</sub>-CH<sub>3</sub>), 0.94–0.87 (m,

$^{12}\text{H}$ ,  $\text{Si}(\text{CH}_2\text{CH}_3)_3$  and  $\text{C}_7\text{-H}_3$ ), 0.60–0.45 (m, 6H,  $\text{Si}(\text{CH}_2\text{CH}_3)_3$ );  $^{13}\text{C}$ -NMR (DMSO- $d_6$ , 100 MHz, 300 K)  $\delta$  215.3, 169.7, 73.1, 65.1, 52.9, 52.7, 49.2, 48.1, 45.1, 40, 38.8, 32.8, 32.1, 26.7, 21.5, 20.9, 21.0, 20.4, 8.5, 7.6, 7.5, 5.4; IR (KBr)  $\nu_{\text{max}}$  2958s, 2913m, 2878s, 1702s, 1391m, 1333s, 1312m, 1267m, 1237m, 1219m, 1166m, 1136s, 1087s, 743m, 539m  $\text{cm}^{-1}$ ; MS (ES+)  $m/z$  (%) 769 (3,  $[\text{3M}+\text{Ca}]^{2+}$ ), 538 (6,  $[\text{M}+\text{K}]^+$ ), 522 (100,  $[\text{M}+\text{Na}]^+$ ), 519 (17,  $[\text{2M}+\text{Ca}]^{2+}$ ), 500 (5,  $[\text{M}+\text{H}]^+$ ).

### EXAMPLE 5

#### Compound 6 with TBDMS Protecting Groups

(see also Fig. 5)

#### **Aldol product (3)**

A solution of **2** (750 mg, 1.50 mmol) in  $\text{CH}_2\text{Cl}_2$  (5.6 ml) at  $-78^\circ\text{C}$  under an atmosphere of argon was treated sequentially with a 0.5 M solution of  $\text{TiCl}_4$  in  $\text{CH}_2\text{Cl}_2$  (3.00 ml, 1.50 mmol) and *N*-ethyldiisopropylamine (257  $\mu\text{l}$ , 1.50 mmol), whereas the solution developed immediately an intense dark red color. After stirring at  $-78^\circ\text{C}$  for 10 min, a solution of **1** (900 mg, 1.65 mmol) in  $\text{CH}_2\text{Cl}_2$  (1.9 ml) was added dropwise. Thereupon, the reaction solution was stirred at  $-78^\circ\text{C}$  for 1 h then warmed-up at  $0^\circ\text{C}$  and stirred for an additional 15 min at which time the reaction was judged complete (TLC). The reaction was quenched at  $0^\circ\text{C}$  by addition of phosphate buffer (pH 7, 4 ml) and dilution with TBME (5 ml). The aqueous layer was extracted with TBME (2 x 5 mL). The combined organic extracts were washed with aqueous saturated  $\text{NaHCO}_3$  (2 x 4 mL) and brine (4 ml), dried with  $\text{MgSO}_4$  and concentrated *in vacuo*. The residue was purified by flash-chromatography (50 g of  $\text{SiO}_2$ , heptane/AcOEt 2:1) to provide the aldol product **3** (1200 mg, 70% based on **1**) as a pale yellowish oil.  $R_f$  = 0.42 ( $\text{SiO}_2$ , 1:2 heptane-AcOEt); MS (ES+)  $m/z$  (%) 1084 (5,  $[\text{M} + \text{K}]^+$ ), 1067 (100,  $[\text{M} + \text{Na}]^+$ ), 1045 (26,  $[\text{M} + \text{H}]^+$ ).

#### **TBDMS ether (4)**

A solution of **3** (1.20 g, 1.15 mmol) in  $\text{CH}_2\text{Cl}_2$  (15 ml) at  $0^\circ\text{C}$  under an atmosphere of argon was treated sequentially with 2,6-lutidine (0.87 ml, 7.49 mmol) and *tert*-butyldimethylsilyl trifluoromethanesulfonate (1.32 ml, 5.74 mmol). After stirring at  $0^\circ\text{C}$  for 14 h, the reaction was worked-up by addition of 0.1 N aqueous HCl (5 mL) along with  $\text{CH}_2\text{Cl}_2$  (5 mL). The layers were separated and the aqueous layer was extracted with  $\text{CH}_2\text{Cl}_2$  (2 x 5 mL). The

combined organic extracts were washed successively with aqueous saturated  $\text{NaHCO}_3$  (2 x 5 mL) and brine (5 mL), dried with  $\text{MgSO}_4$  and concentrated *in vacuo*. The residue was purified by flash-chromatography (50 g of  $\text{SiO}_2$ , heptane/AcOEt 2:1) to provide the compound **16** (893 mg, 67%) as a pale yellowish oil.  $R_f$  = 0.70 ( $\text{SiO}_2$ , 1:2 heptane-AcOEt); MS (ES+)  $m/z$  (%) 1197 (12,  $[\text{M} + \text{K}]^+$ ), 1081 (100,  $[\text{M} + \text{Na}]^+$ ), 1059 (31,  $[\text{M} + \text{H}]^+$ ), 599 (75,  $[\text{M} + \text{Ca}]^{2+}$ ).

### Carboxylic acid (5)

A solution of **4** (318 mg, 0.274 mmol) in 1,2-dimethoxyethane (4.8 ml) at 0 °C was treated sequentially with TBAOH (730  $\mu\text{l}$ , 2.76 mmol) and  $\text{H}_2\text{O}_2$  30% (280  $\mu\text{l}$ , 2.74 mmol) and the resultant mixture was stirred at 0 °C for 5 h before being worked-up: An aqueous saturated solution of  $\text{NH}_4\text{Cl}$  (2 ml) was added along with TBME (2 ml). The layers were separated and the aqueous layer was extracted with TBME (2 x 2 mL). The organic extracts were washed successively with aqueous saturated  $\text{NaHCO}_3$  (2 x 2 mL) and brine (2 mL), combined, dried with  $\text{MgSO}_4$  and concentrated *in vacuo*. The residue was purified by flash-chromatography (15 g of  $\text{SiO}_2$ , heptane/AcOEt 1:1 containing 1% of AcOH) to provide the compound **5** (103 mg, 39%) as a pale yellowish oil.  $R_f$  = 0.41 ( $\text{SiO}_2$ , 3:3:4  $\text{CH}_2\text{Cl}_2$ - $\text{CH}_3\text{CN}$ -hexanes); MS (ES+)  $m/z$  (%) 984 (100,  $[\text{M} + \text{Na}]^+$ ), 962 (12,  $[\text{M} + \text{H}]^+$ ).

### Methyl epoxide (6)

A solution of **5** (78 mg, 0.081 mmol) in THF (1.6 ml) at ambient temperature was treated dropwise with a 1 M solution of  $\text{LiBHET}_3$  in THF (970  $\mu\text{l}$ , 0.97 mmol) and the resultant mixture was stirred at ambient temperature for 1 h. The reaction was quenched by addition of aqueous saturated  $\text{NH}_4\text{Cl}$  (2 ml) along with TBME (2 ml). The layers were separated and the aqueous layer was extracted with TBME (2 x 2 mL). The combined organic extracts were washed successively with aqueous saturated  $\text{NaHCO}_3$  (2 x 2 mL) and brine (2 mL), dried with  $\text{MgSO}_4$  and concentrated *in vacuo*. The residue was purified by flash-chromatography (6 g of  $\text{SiO}_2$ , heptane/AcOEt 1:1 containing 1% of AcOH) to provide the compound **6** (60 mg, 85%) as a pale yellowish oil.  $R_f$  = 0.56 ( $\text{SiO}_2$  1:1 heptane-AcOEt with 1% of AcOH); MS (ES+)  $m/z$  (%) 890 (100,  $[\text{M} + \text{Na}]^+$ ), 868 (50,  $[\text{M} + \text{H}]^+$ ).

### Example 6

#### Aldehyde 1 with one TES and one TBDMS protecting group

(see also Fig. 6)

**(2E,6E)-(S)-5-Hydroxy-2-[(S)-5'-hydroxy-4'-methyl-pentyl]-6-methyl-7-(2''-methyl-thiazol-4''-yl)-hepta-2,6-dienoic acid methyl ester (12)**

In a teflon flask containing 24 ml of HF-pyridine complex (839 mol) at  $-10\text{ }^{\circ}\text{C}$  the allyl ester (XIII) (10.0 g, 16.8 mmol) was added. The resulting mixture was stirred for 10 min at  $-10\text{ }^{\circ}\text{C}$  at which time the reaction was judged complete by disappearance of the starting material (TLC) and immediately quenched. The mixture was poured onto a stirred suspension of  $\text{NaHCO}_3$  (70 g) in water (100 ml) along with TBME (100 ml). The layers were separated and the aqueous phase was extracted with TBME (3 x 80 ml). The organic extracts were combined and were washed with 150 ml of 0.1N HCl and dried over  $\text{MgSO}_4$ . Concentration *in vacuo* provided the crude diol (2) (6.34 g) which was directly subjected to the next reaction.  $R_f = 0.06$  ( $\text{SiO}_2$ , 1:1 heptane-AcOEt);  $^1\text{H-NMR}$  ( $\text{DMSO-d}_6$ , 300 MHz, 300 K)  $\delta$  6.90 (s, 1H,  $\text{C}_5\text{-H}$ ), 6.75 (t, 1H,  $J = 7.5\text{ Hz}$ ,  $\text{C}_3\text{-H}$ ), 6.51 (s, 1H,  $\text{C}_7\text{-H}$ ), 4.23 (t,  $J = 6.3\text{ Hz}$ , 1H,  $\text{C}_3\text{-H}$ ), 3.65 (s, 3H,  $\text{CO}_2\text{CH}_3$ ), 3.41 (dd,  $J = 10.5, 6.0\text{ Hz}$ , 1H,  $\text{C}_5\text{-H}_a$ ), 3.34 (dd,  $J = 10.5, 6.3\text{ Hz}$ , 1H,  $\text{C}_5\text{-H}_b$ ), 2.64 (s, 3H,  $\text{C}_2\text{-CH}_3$ ), 2.46 (t,  $J = 6.9\text{ Hz}$ , 2H,  $\text{C}_4\text{-H}_2$ ), 2.25 (t,  $J = 7.2\text{ Hz}$ , 2H,  $\text{C}_1\text{-H}_2$ ), 2.00 (s, 3H,  $\text{C}_6\text{-CH}_3$ ), 1.70–1.55 and 1.53–1.25 (2 br m, 6 H,  $\text{C}_2\text{-H}_2$ ,  $\text{C}_3\text{-H}_a$ ,  $\text{C}_4\text{-H}$ ,  $\text{C}_5\text{-OH}$  and  $\text{C}_5\text{-OH}$ ), 1.15–1.00 (m, 1 H,  $\text{C}_3\text{-H}_b$ ), 0.85 (d,  $J = 6.6\text{ Hz}$ , 3H,  $\text{C}_4\text{-CH}_3$ ).

**(2E,6E)-(S)-6-Methyl-7-(2'-methyl-thiazol-4'-yl)-2-[(S)-4''-methyl-5''-triethylsilanyloxy-pentyl]-5-triethylsilanyloxy-hepta-2,6-dienoic acid methyl ester (XIII')**

A solution of crude diol (12) (6.33 g, 14 mmol) in  $\text{CH}_2\text{Cl}_2$  (150 ml) at  $0\text{ }^{\circ}\text{C}$ , was treated sequentially with *N*-ethyl-diisopropylamine (23.6 ml, 138 mmol), 4-(*N,N*-dimethylamino)-pyridine (70 mg, 0.57 mmol) and triethylchlorosilane (10.9 ml, 86.1 mmol). The resulting solution was stirred at ambient temperature overnight. The reaction was quenched with a saturated aqueous solution of  $\text{NaHCO}_3$  (150 ml) and the aqueous layer was extracted with  $\text{CH}_2\text{Cl}_2$  (3 x 200 ml). The organic extracts were combined, washed with 200 ml of brine, dried over  $\text{MgSO}_4$  and concentrated *in vacuo*. Purification of the residue by chromatography ( $\text{SiO}_2$ , 20-30% hexanes/AcOEt gradient elution) afforded 8.6 g (86 % over two steps) of TES protected diol (XIII').  $R_f = 0.63$  ( $\text{SiO}_2$ , 1:1 heptane-AcOEt);  $^1\text{H-NMR}$  ( $\text{DMSO-d}_6$ , 400 MHz, 300 K)  $\delta$  7.26 (s,  $\delta$ ,  $\text{C}_5\text{-H}$ ), 6.73 (t,  $J = 7.3\text{ Hz}$ , 1H,  $\text{C}_3\text{-H}$ ), 6.48 (s, 1H,  $\text{C}_7\text{-H}$ ), 4.30 (t,  $J = 6.7\text{ Hz}$ , 1H,  $\text{C}_5\text{-H}$ ), 3.65 (s, 3H,  $\text{CO}_2\text{CH}_3$ ), 3.41 (dd,  $J = 9.8, 5.9\text{ Hz}$ , 1H,  $\text{C}_5\text{-H}_a$ ), 3.36 (dd,  $J = 9.8, 6.3\text{ Hz}$ , 1H,  $\text{C}_5\text{-H}_b$ ), 2.66 (s, 3H,  $\text{C}_2\text{-CH}_3$ ), 2.45 (t,  $J = 6.7\text{ Hz}$ , 2H,  $\text{C}_4\text{-H}_2$ ), 2.30–2.20 (br m, 2H,  $\text{C}_1\text{-H}_2$ ), 2.04 (s, 3H,  $\text{C}_6\text{-CH}_3$ ), 1.59–1.47 (br m, 1H,  $\text{C}_4\text{-H}$ ), 1.45–1.23 (br m, 3H,  $\text{C}_2\text{-H}_2$

and C<sub>3</sub>-H<sub>a</sub>), 1.01–1.00 (br m, 1H, C<sub>3</sub>-H<sub>b</sub>), 0.98–0.88 (m, 18H, two Si(CH<sub>2</sub>CH<sub>3</sub>)<sub>3</sub>), 0.83 (d, *J* = 6.9 Hz, 3H, C<sub>4</sub>-CH<sub>3</sub>), 0.62–0.52 (m, 12H, two Si(CH<sub>2</sub>CH<sub>3</sub>)<sub>3</sub>); IR (film)  $\nu_{\max}$  2953s, 2934s, 2913s, 2875s, 1713s, 1644w, 1505w, 1459m, 1437m, 1414w, 1376w, 1285m, 1269m, 1241m, 1185m, 1120m, 1072m, 1006m, 744m, 723s cm<sup>-1</sup>; MS (ES+) *m/z* (%) 618 (100, [M + Na]<sup>+</sup>), 596 (72, [M + H]<sup>+</sup>).

**(2*E*,6*E*)-(S)-6-Methyl-7-(2'-methyl-thiazol-4'-yl)-2-[(S)-4''-methyl-5''-triethylsilyloxy-pentyl]-5-triethylsilyloxy-hepta-2,6-dien-1-ol (XIV)**

To a solution of allyl ester (XIII') (45.54 g, 76.4 mmol) in THF (250 ml), was added DIBAL-H 1.5 M in toluene (153 ml, 229 mmol) at –78 °C. The resulting mixture was stirred for 3 h at –78 °C. The reaction was quenched by slow addition of 115 ml of 2N HCl and diluted with 100 ml of TBME. The layers were separated and the aqueous phase was extracted with TBME (2 x 100 ml). The combined organic layers were washed with 100 ml of NaHCO<sub>3</sub>, followed by 100 ml of brine and dried over MgSO<sub>4</sub>. Concentration *in vacuo* provided 51.53 g of crude allyl alcohol which was chromatographed (SiO<sub>2</sub>, 20–40% hexanes/AcOEt gradient elution) to give 32.5 g (75 %) of pure allyl alcohol (XIV). *R<sub>f</sub>* = 0.47 (SiO<sub>2</sub>, 1:1 heptane-AcOEt); <sup>1</sup>H-NMR (DMSO-d<sub>6</sub>, 500 MHz, 300 K)  $\delta$  7.29 (s, 1H, C<sub>5</sub>-H), 6.38 (s, 1H, C<sub>7</sub>-H), 5.29 (t, *J* = 7.1 Hz, 1H, C<sub>3</sub>-H), 4.60 (t, *J* = 5.4 Hz, 1H, C<sub>1</sub>-OH), 4.10 (t, *J* = 6.4 Hz, 1H, C<sub>5</sub>-H), 3.79 (d, *J* = 5.1 Hz, 2H, C<sub>1</sub>-H<sub>2</sub>), 3.40 (dd, *J* = 9.8, 5.9 Hz, 1H, C<sub>5</sub>-H<sub>a</sub>), 3.33 (dd, *J* = 9.8, 6.5 Hz, 1H, C<sub>5</sub>-H<sub>b</sub>), 2.64 (s, 3H, C<sub>2</sub>-CH<sub>3</sub>), 2.25 (t, *J* = 6.8 Hz, 2H, C<sub>4</sub>-H<sub>2</sub>), 1.99 (s, 3H, C<sub>6</sub>-CH<sub>3</sub>), 2.00–1.90 (br m, 2H, C<sub>1</sub>-H<sub>2</sub>), 1.58–1.46 (m, 1H, C<sub>4</sub>-H), 1.43–1.22 (m, 3H, C<sub>3</sub>-H<sub>a</sub> and C<sub>2</sub>-H<sub>2</sub>), 1.08–0.97 (m, 1H, C<sub>3</sub>-H<sub>b</sub>), 0.95–0.85 (m, 18H, two Si(CH<sub>2</sub>CH<sub>3</sub>)<sub>3</sub>), 0.82 (d, *J* = 6.7 Hz, 3H, C<sub>4</sub>-CH<sub>3</sub>), 0.58–0.50 (m, 12H, two Si(CH<sub>2</sub>CH<sub>3</sub>)<sub>3</sub>); <sup>13</sup>C-NMR (DMSO-d<sub>6</sub>, 125 MHz, 300 K)  $\delta$  164.1, 152.5, 141.1, 140.7, 119.9, 118.4, 116.6, 78.0, 67.3, 64.6, 35.2, 34.4, 32.9, 28.0, 25.4, 18.9, 16.6, 13.7, 6.74, 6.72, 4.3, 4.0; IR (film)  $\nu_{\max}$  3341s (br), 2952s, 2932s, 2874s, 1508m, 1458m, 1414m, 1378w, 1238w, 1190m, 1071s, 1016s, 883w, 829w, 743m, 728m cm<sup>-1</sup>; MS (ES+) *m/z* (%) 590 (28, [M + Na]<sup>+</sup>), 568 (100, [M + H]<sup>+</sup>).

**{(2*S*,3*S*)-3-[(*E*)-(S)-3'-Methyl-4'-(2''-methyl-thiazol-4''-yl)-2-triethylsilyloxy-but-3-enyl]-2-[(S)-4'''-methyl-5'''-triethylsilyloxy-pentyl]-oxiranyl}-methanol (XV)**

In a dried flask and under argon, 5.00 g (8.80 mmol) of allyl alcohol (4) was dissolved in 100 ml of CH<sub>2</sub>Cl<sub>2</sub>. Molecular sieve 4Å (4 g) was added and the temperature of the mixture was set to –30°C. (+)-Diethyl-L-tartrate (7.46 ml, 4.40 mmol) followed by titanium(IV)isopropoxide (10.35 ml, 3.52 mmol) were added. The resulting mixture was stirred 1 h at –30°C whereas

the solution gradually developed a yellow-green color. Then, 3.52 ml of *tert*-butylhydroperoxide (19.36 mmol) were added. The reaction was left overnight at  $-25^{\circ}\text{C}$  and was quenched with 100 ml of  $\text{NaHSO}_3$  and well stirred. The filtrate was extracted with TBME (2 x 80 ml). The combined organic layers were washed with 80 ml of brine, dried over  $\text{MgSO}_4$  and concentrated *in vacuo* to provided 7.24 g of crude product. After purification by chromatography (1:1 hexanes/AcOEt), 5.2 g (100%) of epoxyalcohol (XV) were obtained.  $R_f = 0.38$  ( $\text{SiO}_2$ , 1:1 heptane-AcOEt);  $^1\text{H-NMR}$  ( $\text{DMSO-d}_6$ , 400 MHz, 300 K)  $\delta$  7.28 (s, 1H,  $\text{C}_5\text{-H}$ ), 6.44 (s, 1H,  $\text{C}_4\text{-H}$ ), 4.30 (dd,  $J = 8.2, 4.1$  Hz, 1H,  $\text{C}_2\text{-H}$ ), 3.46 (d,  $J = 12.2$  Hz, 1H,  $\text{C}_1\text{-H}_a$ ), 3.39 (dd,  $J = 10.2, 6.0$  Hz, 1H,  $\text{C}_5\text{-H}_a$ ), 3.34 (dd,  $J = 10.2, 6.2$  Hz, 1H,  $\text{C}_5\text{-H}_b$ ), 3.27 (d,  $J = 12.2$  Hz, 1H,  $\text{C}_1\text{-H}_b$ ), 2.90 (dd,  $J = 7.3, 4.6$  Hz, 1H,  $\text{C}_3\text{-H}$ ), 2.63 (s, 3H,  $\text{C}_2\text{-CH}_3$ ), 1.98 (s, 3H,  $\text{C}_3\text{-CH}_3$ ), 1.81 (ddd,  $J = 12.3, 8.2, 4.6$  Hz, 1H,  $\text{C}_1\text{-H}_a$ ), 1.68–1.20 (4 m, 7H,  $\text{C}_1\text{-H}_b$ ,  $\text{C}_1\text{-H}_2$ ,  $\text{C}_2\text{-H}_2$ ,  $\text{C}_3\text{-H}_a$ ,  $\text{C}_4\text{-H}_1$ ), 1.08–0.98 (m, 1H,  $\text{C}_3\text{-H}_b$ ), 0.93–0.83 (m, 18H, two  $\text{Si}(\text{CH}_2\text{CH}_3)_3$ ), 0.82 (d,  $J = 6.7$  Hz, 3H,  $\text{C}_4\text{-CH}_3$ ), 0.59–0.50 (m, 12H, two  $\text{Si}(\text{CH}_2\text{CH}_3)_3$ );  $^{13}\text{C-NMR}$  ( $\text{DMSO-d}_6$ , 125 MHz, 300 K)  $\delta$  164.7, 152.6, 141.2, 118.7, 117.1, 76.3, 67.6, 63.6, 63.6, 60.2, 57.5, 35.5, 35.4, 33.3, 28.7, 22.3, 19.1, 16.8, 14.4, 13.9, 7.1, 7.0, 4.6, 4.3; IR (film)  $\nu_{\text{max}}$  3403s (br), 2954s, 2876s, 1507m, 1459m, 1414m, 1377m, 1239m, 1185m, 1084s, 1007s, 976w, 802w, 744s, 676w  $\text{cm}^{-1}$ ; MS (ES)  $m/z$  (%) 606 (52,  $[\text{M} + \text{Na}]^+$ ), 584 (100,  $[\text{M} + \text{H}]^+$ ).

**Methanesulfonic acid (2*S*,3*S*)-3-[(*E*)-(*S*)-3'-methyl-4'-(2''-methyl-thiazol-4''-yl)-2-triethylsilanyloxy-but-3-enyl]-2-[(*S*)-4'''-methyl-5'''-triethylsilanyloxy-pentyl]-oxiranylmethyl ester (XVI)**

To a solution of epoxyalcohol (XV) (11.71 g, 20.0 mmol) in  $\text{CH}_2\text{Cl}_2$  (148 ml), was added 10.3 ml (60.1 mmol) of *N*-ethyl-diisopropylamine at  $0^{\circ}\text{C}$ . The resulting mixture was stirred 15 min. at  $0^{\circ}\text{C}$ . Thereupon, methanesulfonylchloride was added (2.33 ml, 30.1 mmol). After stirring for 1 h at  $0^{\circ}\text{C}$ , the reaction solution was quenched with 50 ml of  $\text{H}_2\text{O}$  and 50 ml of TBME. The layers were separated and the aqueous layer was washed with TBME (50 ml). The combined organic extracts were washed with 0.1N HCl (40 ml), saturated aqueous  $\text{NaHCO}_3$  (2 x 40 ml) and brine (50 ml) and dried over  $\text{MgSO}_4$ . Concentration *in vacuo* provided 13.7 g of epoxy mesylate (XVI) which did not require any further purification.  $R_f = 0.55$  ( $\text{SiO}_2$ , 1:1 heptane-AcOEt);  $^1\text{H-NMR}$  ( $\text{DMSO-d}_6$ , 400 MHz, 300 K)  $\delta$  7.34 (s, 1H,  $\text{C}_5\text{-H}$ ), 6.49 (s, 1H,  $\text{C}_4\text{-H}$ ), 4.38 (d,  $J = 11.4$  Hz, 1H,  $\text{C}_1\text{-H}_a$ ), 4.34 (dd,  $J = 8.2, 3.7$  Hz, 1H,  $\text{C}_2\text{-H}$ ), 4.07 (d,  $J = 11.4$  Hz, 1H,  $\text{C}_1\text{-H}_b$ ), 3.43 (dd,  $J = 9.8, 5.9$  Hz, 1H,  $\text{C}_5\text{-H}_a$ ), 3.37 (dd,  $J = 9.8, 6.3$  Hz, 1H,  $\text{C}_5\text{-H}_b$ ), 3.33 (s, 3H,  $\text{SO}_2\text{CH}_3$ ), 3.06 (dd,  $J = 7.0, 4.6$  Hz, 1H,  $\text{C}_3\text{-H}$ ), 2.66 (s, 3H,  $\text{C}_2\text{-CH}_3$ ), 2.03 (s, 3H,  $\text{C}_3\text{-CH}_3$ ), 1.89 (ddd,  $J = 15.2, 7.0, 3.7$  Hz, 1H,  $\text{C}_1\text{-H}_a$ ), 1.77–1.20 (5 m, 7H,  $\text{C}_1\text{-H}_b$ ,



$C_{1''}-H_2$ ,  $C_{2''}-H_2$ ,  $C_{3''}-H_a$ ,  $C_{4''}-H$ , 1.12–1.03 (m, 1H,  $C_{3''}-H_b$ ), 0.97–0.88 (m, 18H, two  $Si(CH_2CH_3)_3$ ), 0.85 (d,  $J = 6.6$  Hz, 3H,  $C_{4''}-CH_3$ ), 0.63–0.50 (m, 12H, two  $Si(CH_2CH_3)_3$ );  $^{13}C$ -NMR (DMSO- $d_6$ , 125 MHz, 300 K)  $\delta$  164.2, 152.3, 140.5, 118.6, 117.0, 75.8, 72.1, 67.2, 60.4, 57.8, 36.6, 35.1, 34.6, 32.8, 28.1, 21.7, 18.9, 16.5, 13.6, 6.8, 6.7, 4.3, 4.0; MS (ES+)  $m/z$  (%) 684 (100,  $[M + Na]^+$ ), 662 (54,  $[M + H]^+$ ).

**Methanesulfonic acid (2S,3S)-2-[(S)-5'-hydroxy-4'-methyl-pentyl]-3-[(E)-(S)-3''-methyl-4''-(2''-methyl-thiazol-4''-yl)-2-triethylsilanyloxy-but-3-enyl]-oxiranylmethyl ester (XVII)**

A solution of bis-TES ether (XVI) (4.89 g, 7.38 mmol) in THF/AcOH/H<sub>2</sub>O (10:2:1 v/v/v, 115 ml) was heated at 50°C for 15 h. To quench the reaction, 460 ml of saturated aqueous solution of NaHCO<sub>3</sub> was added and the mixture was extracted with TBME (2 x 250 ml). The organic layers were combined and washed with brine, dried over MgSO<sub>4</sub> and concentrated *in vacuo* to give 4.73 g of crude product. Purification by flash-chromatography (SiO<sub>2</sub>; 30–60% AcOEt/hexane gradient elution) afforded 3.10 g (79 % over two steps based on XV) of alcohol (XVII).  $R_f = 0.15$  (SiO<sub>2</sub>, 1:1 heptane-AcOEt);  $^1H$ -NMR (DMSO- $d_6$ , 400 MHz, 300 K)  $\delta$  7.42 (s, 1H,  $C_{5''}-H$ ), 6.50 (s, 1H,  $C_{4''}-H$ ), 4.38 (d,  $J = 11.3$  Hz, 1H,  $C_1-H_a$ ), 4.36 (dd,  $J = 8.3$ , 4.6 Hz, 1H,  $C_{2''}-H$ , partially obscured by  $C_1-H_a$ ), 4.07 (d,  $J = 11.8$  Hz, 1H,  $C_1-H_a$ ), 3.30–3.23 (m, 1H,  $C_{5''}-H_a$ ), 3.20 (s, 3H, SO<sub>2</sub>CH<sub>3</sub>), 3.22–3.14 (m, 1H,  $C_{5''}-H_b$ , partially obscured by SO<sub>2</sub>CH<sub>3</sub>), 3.06 (dd,  $J = 7.1$ , 4.4 Hz, 1H,  $C_3-H$ ), 2.67 (s, 3H,  $C_{2''}-CH_3$ ), 2.04 (s, 3H,  $C_{3''}-CH_3$ ), 1.90 (ddd,  $J = 14.2$ , 8.3, 4.4 Hz, 1H,  $C_{1''}-H_a$ ), 1.70–1.58 (m, 1H,  $C_{1''}-H_b$ ), 1.54–1.32 (m, 6H,  $C_{1''}-H_2$ ,  $C_{2''}-H_2$ ,  $C_{3''}-H_a$ ,  $C_{4''}-H$ ), 1.10–0.98 (m, 1H,  $C_{3''}-H_b$ ), 0.93 (t,  $J = 8.0$  Hz, 9H,  $Si(CH_2CH_3)_3$ ), 0.84 (d,  $J = 6.6$  Hz, 3H,  $C_{4''}-CH_3$ ), 0.60 (q,  $J = 8.0$  Hz, 6H,  $Si(CH_2CH_3)_3$ );  $^{13}C$ -NMR (DMSO- $d_6$ , 100 MHz, 300 K)  $\delta$  165.1, 153.2, 141.5, 119.4, 117.9, 76.6, 73.3, 67.0, 61.2, 58.6, 37.6, 36.0, 35.5, 33.9, 29.0, 22.6, 19.7, 17.5, 14.9, 14.5, 7.63, 7.58, 5.1; IR (film)  $\nu_{max}$  3410s (br), 2955s, 2876s, 1655w, 1505w, 1459m, 1414m, 1359s, 1270w, 1239w, 1177s, 1081m, 1006m, 958m, 833m, 745m, 529m cm<sup>-1</sup>; MS (ES+)  $m/z$  (%) 586 (5,  $[M+K]^+$ ), 570 (100,  $[M+Na]^+$ ), 548 (8,  $[M+H]^+$ ).

**Methanesulfonic acid (2S,3S)-3-[(E)-(S)-3'-methyl-4'-(2''-methyl-thiazol-4''-yl)-2-triethylsilanyloxy-but-3-enyl]-2-[(S)-4'''-methyl-5'''-oxo-pentyl]-oxiranylmethyl ester (1)**

To a solution of alcohol (XVII) (2.00 g, 3.65 mmol) in CH<sub>2</sub>Cl<sub>2</sub> (10 ml) at 0°C was added sequentially triethylamine (3.86 ml, 27.7 mmol), DMSO (6.48 ml, 91.3 mmol) and pyridinium-SO<sub>3</sub> complex (2.32 g, 14.6 mmol) in DMSO (26 ml). The resulting solution was


stirred 1 h at 0 °C. The reaction was quenched with a aqueous solution of NaHSO<sub>4</sub> (40%, 120 ml) and TBME (150 ml). The layers were separated and the organic layer was washed with saturated aqueous NaHCO<sub>3</sub> (2 x 100 ml). These aqueous layers were back-extracted with TBME (2 x 100 ml). The organic extracts were combined and washed with brine (100 ml), dried over MgSO<sub>4</sub> and concentrated *in vacuo* to give 1.94 g of crude product.

Purification by flash-chromatography (SiO<sub>2</sub>, 50–70% AcOEt/hexane gradient elution) provided 1.63 g (82 %) of pure aldehyde (1). *R<sub>f</sub>* = 0.30 (SiO<sub>2</sub>, 1:1 heptane-AcOEt); <sup>1</sup>H-NMR (CDCl<sub>3</sub>, 500 MHz, 300 K) δ 9.61 (d, *J* = 1.7 Hz, 1H, CHO), 6.95 (s, 1H, C<sub>5</sub><sup>'''</sup>-H), 6.52 (s, 1H, C<sub>4</sub>-H), 4.33 (dd, *J* = 4.4 Hz, 1H, C<sub>2</sub><sup>''</sup>-H, partially obscured by C<sub>1</sub>-H<sub>a</sub>), 4.34 (d, *J* = 11.4 Hz, 1H, C<sub>1</sub>-H<sub>a</sub>), 4.08 (d, *J* = 11.4 Hz, 1H, C<sub>1</sub>-H<sub>b</sub>), 3.11 (dd, *J* = 7.8, 3.9 Hz, 1H, C<sub>3</sub>-H), 3.05 (s, 3H, SO<sub>2</sub>CH<sub>3</sub>), 2.71 (s, 3H, C<sub>2</sub><sup>'''</sup>-CH<sub>3</sub>), 2.33 (m, 1H, C<sub>4</sub><sup>'''</sup>-H), 2.02 (s, 3H, C<sub>3</sub><sup>''</sup>-CH<sub>3</sub>), 1.99–1.32 (6 m, 8H, C<sub>1</sub><sup>''</sup>-H<sub>2</sub>, C<sub>1</sub><sup>'''</sup>-H<sub>2</sub>, C<sub>2</sub><sup>'''</sup>-H<sub>2</sub>, C<sub>3</sub><sup>'''</sup>-H<sub>2</sub>), 1.11 (d, *J* = 7.1 Hz, 3H, C<sub>4</sub><sup>'''</sup>-CH<sub>3</sub>), 0.94 (t, *J* = 8.0 Hz, 9H, Si(CH<sub>2</sub>CH<sub>3</sub>)<sub>3</sub>), 0.61 (q, *J* = 8.0 Hz, 6H, Si(CH<sub>2</sub>CH<sub>3</sub>)<sub>3</sub>); <sup>13</sup>C-NMR (CDCl<sub>3</sub>, 125 MHz, 300 K) δ 204.7, 164.8, 152.8, 141.8, 119.2, 115.8, 76.0, 72.0, 60.7, 59.0, 46.3, 37.8, 35.3, 30.5, 28.3, 22.5, 19.4, 14.1, 13.5, 7.0, 4.9 ; ; IR (film) ν 2956s, 2876s, 2720w, 1724s, 1658w, 1508m, 1459m, 1414w, 1358s, 1240w, 1177s, 1079m, 1006m, 957m, 883w, 828m, 745m, 529m cm<sup>-1</sup>; MS (ES+) *m/z* 546 (100, [M+H]<sup>+</sup>).MS (ES+) *m/z* 546 (100, [M+H]<sup>+</sup>).

What we claim is:

---


1. Process for the preparation of epothilone derivatives of formula 9



wherein


R1 is methyl and R2 has the meaning of an unsubstituted or substituted aryl, an unsubstituted or substituted heteroaryl or an unsubstituted or substituted heterocyclic radical fused to a benzene nucleus and salts thereof with metal cations, characterised by

a) reacting a compound of formula 1




wherein R2 has the meanings given above and the mesylate group may be replaced by a tosylate group and the like and the tert.butyl-dimethyl silyl protecting group may be replaced by any of the earlier listed silylether forming groups, e.g. TES in all following reaction sequences, with a sultam derived compound of formula 2 as, for example,

---



(2)


in a selective aldol reaction in the presence of a Lewis acid and addition of a base in an inert solvent at lower temperatures between -50° to -100°C and thereafter at elevated temperatures between -20° to +20°C obtaining a compound of formula 3



(3)


wherein R<sub>2</sub> has the above given meanings, and

b) the obtained compounds of above formula 3 are reacted at temperatures between  $-70^{\circ}$  and  $25^{\circ}$  C in the presence of a silyl-ether forming compound and 2,6-lutidine forming compounds of formula 4




wherein  $R_2$  has the meanings given above, and

c) converting an above compound of formula 4 to the carboxylic acid by splitting off the chiral auxillary group with TBAOH/ $H_2O_2$  in DME or  $LiO_2H$  in THF/MeOH/ $H_2O$  obtaining a compound of formula 5




wherein R<sub>2</sub> has the meanings given above, and

d) reacting compounds of above formula 5 with a reducing reagent in an inert solvent cleaving the mesylate or tosylate group or the like obtaining a compound of formula 6




wherein R<sub>2</sub> has the above given meanings.

e) hydrolysing the tri-protected tris-silylether compounds of above formula 6 with a desilylation reagent or an acid in an inert solvent or a mixture thereof, e.g. TASF or HF-pyridine in THF, obtaining a selectively desilylated compound of formula 7




wherein R<sub>2</sub> has the above given meanings, and

f) macrolactonizing obtained compounds of formula 7 according to the conditions described by M. Yamaguchi et al Bull.Chem.Soc.Jpn.,1979, 52 ,1989, obtaining a fully protected epothilone derivative of formula 8



wherein both the silyl protecting groups TBDMS or one TBDMS group may be replaced by the TES silyl protecting group and R<sub>2</sub> has the above defined meanings, and

g) treating an obtained compound of formula 8 with HF-pyridine in an inert solvent at temperatures between 0° and 30 °C and cleaving both silyl protecting groups obtaining epothilone derivatives of formula 9



wherein R1 is methyl and R2 has the above described meanings and optionally converting compounds of formula 9 wherein R1 and R2 have the defined meanings under formula 9 to a salt with metal cations by conventional methods.

2. Process according to step a) of claim 1, characterised, that compounds of formula 1 are reacted with a compound of formula 2, for example, in the presence of  $\text{TiCl}_4$  and Hünig base ( $\text{iPr}_2\text{Net}$ ) in dichloromethane at a temperature of  $-78^\circ\text{C}$  and thereafter at a temperature of  $0^\circ\text{C}$  obtaining new compounds of formula 3.

3. Process according to step b) of claim 1, characterised that obtained compounds of formula 3 are reacted with TBDMSOTf as a silyl-ether forming compound in the presence of 2,6-lutidine at temperatures between  $-20^\circ$  and  $+20^\circ\text{C}$ , especially at a temperature of  $-10^\circ\text{C}$  in dichloromethane as inert solvent forming compounds of formula 4.

4. Process according to step c) of claim 1, characterised that obtained compounds of formula 4 are converted to the carboxylic acid by splitting off the chiral auxillary group with TBAOH/ $\text{H}_2\text{O}_2$  in DME or  $\text{LiO}_2\text{H}$  in THF/ $\text{MeOH}/\text{H}_2\text{O}$  obtaining a compound of formula 5.

5. Process according to step d) of claim 1, characterised that obtained compounds of formula 5 are reacted with  $\text{LiBHET}_3$  as reducing reagent in THF as inert solvent for cleaving the mesylate or tosylate group or the like obtaining a compound of formula 6.


6. Process according to step e) of claim 1, characterized that obtained compounds of formula 6 are hydrolysed with a desilylation reagent especially with TASF or an organic acid especially  $\text{HF}\cdot\text{pyridine}$  in an inert solvent, e.g. pyridine or THF, obtaining compounds of formula 7.

7. Process according to step f) of claim 1, characterised that obtained compounds of formula 7 are macrolactonized according to Yamaguchi et al, e.g. treating the hydroxy-acid with  $\text{Et}_3\text{N}$  and 2,4,6-trichlorobenzoyl chloride at lower temperature, e.g.  $0^\circ\text{C}$  and thereafter the reaction mixture is added to a solution of 4-DMAP in toluene and the temperature raised to ca.  $75^\circ\text{C}$  obtaining compounds of formula 8.




8. Process according to step g) of claim 1, characterized that obtained protected epothilone derivatives of formula 8 are treated with HF-pyridine in pyridine as inert solvent and after cleavage of both silyl ether protecting groups (TBDMS) epothilone derivatives of formula 9 are obtained and optionally converting compounds of formula 9 wherein R1 and R2 have the defined meanings under formula 9 to a salt with metal cations by conventional methods.

9. Compounds of formula 9



wherein R1 is methyl and R2 is an unsubstituted or substituted aryl and salts with metal cations.

10. Compounds of formula 9




wherein R1 is methyl and R2 is an unsubstituted or substituted phenyl and salts with metal cations.

The chemical structure shows a complex dendritic polymer. It features a central carbon atom bonded to a hydroxyl group (HO-), a carbonyl group (C=O), a sulfonamide group (-SO<sub>2</sub>N-), and a sulfonate group (-SO<sub>3</sub><sup>-</sup>). The sulfonamide group is attached to a bicyclic system. The sulfonate group is attached to a chain that includes a sulfonate group (-SO<sub>3</sub><sup>-</sup>) and a sulfonamide group (-SO<sub>2</sub>N-). The structure also includes a silicon atom (Si) bonded to a tert-butyl group and a sulfonate group (-SO<sub>3</sub><sup>-</sup>). The overall structure is highly branched and contains multiple functional groups.

wherein R2 has the meanings given under formula 9.


wherein R2 has the above given meanings and the mesylate group may be replaced by a tosylate group and the like in all following reaction sequences with a sultam derived compound of formula 2 as for example



(2)


in a selective aldol reaction in the presence of a Lewis acid and addition of a base in an inert solvent at lower temperatures between  $-50^{\circ}$  to  $-100^{\circ}$  °C and thereafter at elevated temperatures between  $-20^{\circ}$  to  $+20^{\circ}$  °C obtaining a compound of formula 3.

13. Compounds of formula 4




wherein R2 has the above meanings.

14. Process for the production of new compounds of formula 4, characterised that compounds of formula 3




are reacted at temperatures between  $-70^{\circ}$  and  $25^{\circ}\text{C}$  in the presence of a silyl-ether forming compound, eg. TBMDs and in the presence of 2,6-lutidine forming compounds of above given formula 4.

15. Compounds of formula 5




wherein  $\text{R}_2$  has the meanings given above.

16. Process for the production of new compounds of formula 5 characterised that compounds of formula 4




are converted to carboxylic acids by splitting off the chiral auxillary group with TBAOH/H<sub>2</sub>O<sub>2</sub> in DME or LiO<sub>2</sub>H in THFMeOH//H<sub>2</sub>O obtaining a compound of formula 5.

17. Compounds of formula 6




wherein R<sub>2</sub> has the above given meanings.)

18. Process for the production of new compounds of formula 6, characterised in that compounds of formula 5



are reacted with a reducing reagent in an inert solvent cleaving the mesylate group or tosylate group or the like obtaining a compound of above formula 6.


19. Compounds of formula 7



wherein R<sub>2</sub> has the above given meanings.


20. Process for the preparation of new compounds of formula 7, characterised by hydrolysing the tri-protected tris-silylether compounds of above formula 6 with a desilylation reagent, especially TASF or an organic acid, especially HF-pyridine in an inert solvent, e.g. pyridine or THF, obtaining a compound of formula 7.

21. Compounds of formula 8




wherein R<sub>2</sub> has the above given meanings.

22. Process for the production of compounds of formula 8, characterised by macrolactonizing compounds of formula 7 according to the conditions described by M. Yamaguchi et al Bull.Chem.Soc.Jpn.,1979, 52 ,1989, obtaining a fully protected epothilone derivative of formula 8



wherein R<sub>2</sub> has the above given meanings.

23. Compounds of formula 1




(1)

wherein R<sub>2</sub> has the meaning of an unsubstituted or substituted aryl, an unsubstituted or substituted heteroaryl or an unsubstituted or substituted heterocyclic radical fused to a benzene nucleus.


24. Process for the production of compounds of formula 1, characterised by

a) reacting tert.butyl-1-(S)-6-iodo-2-methyl-hexyloxy-dimethyl-silane of formula X



(X)

with PPH<sub>3</sub> at temperatures between 50° - 150 °C, more precisely at a temperature 100° C and thereafter with KHMDS in an inert solvent, especially in THF at 0 °C and thereafter cooling the reaction mixture to a temperature between -50° to -100 ° C and treating with CH<sub>3</sub>CO<sub>2</sub>Cl more precisely at a temperature of -78 °C obtaining a compound of formula XI




(XI)

and,


b) reacting the obtained compound of formula XI with a compound of formula XII






(XII)

in an inert solvent, e.g. in toluene at temperatures between 20° to 60 °C, more precisely at a temperature of 40 °C obtaining a compound of formula XIII



(XIII)

c) reducing a compound of formula (XIII) with a reducing reagent, especially with DIBALH, in an inert solvent, e.g. toluene at temperatures between -50 ° to -100 °C, more precisely at a temperature of -78 °C and thereafter elevating the temperature to 0 °C obtaining a compound of formula XIV




(XIV)

(the drawing of formula XIV and the formulae thereafter have been simplified)


R<sub>2</sub> has the above given meanings, and

d) using the conditions under Sharpless [(+)-diethyl-L-tartrate, Ti(OPr)<sub>4</sub>, t-BuOOH] for epoxidation obtaining a compound of formula XV



wherein the PGs (the protecting groups TBDMS may be replaced by other protecting groups, especially by TES and the like and R<sub>2</sub> has the above given meanings under formula 9, and


e) introducing the mesylate group into a compound of formula XV by adding mesylate chloride (the mesylate group may be replaced by a tosylate group or the like) in the presence of triethylamine (Et<sub>3</sub>N) in an inert solvent, e.g. dichloromethane obtaining a compound of formula XVI



wherein R<sub>2</sub> has the above given meaning, and

f) treating the obtained compound of formula XVI with an organic acid, in an inert solvent, more precisely with pyridinium p-toluenesulfonate or camphor sulfonic acid in absolute


ethanol, hydrolysing the one TBDMS protecting group and obtaining a compound of formula XVII



(XVII)

wherein R<sub>2</sub> has the above given meanings, and


g) oxidizing by using the Swern-oxidation method, e.g. oxidizing the alcoholic group by the promotion of oxalyl chloride and activation of dimethyl sulfoxide, passing the alkoxysulfonium salts and after addition of a base and intramolecularly rearrangement obtaining a keto compound of formula 1



(1)

wherein R<sub>2</sub> has the above given meanings.


## 25. Compounds of formula XV



or wherein both the protecting groups of formula XV may be replaced by TES protecting groups or the like.


wherein R<sub>2</sub> has the above given meanings.

26. Process for the production of compounds of formula XV, characterised by using the conditions under Sharpless [(+)-diethyl-L-tartrate, Ti(OPr)<sub>4</sub>, t-BuOOH] for epoxidation of above compound of formula XIV obtaining a compound of formula XV




wherein both the PGs TBDMS may be replaced by TES groups or the like and R<sub>2</sub> has the above given meanings under formula 9, and

## 27. Compounds of formula XVI




wherein both TBDMS protecting may be replaced by TES protecting groups or the like and R<sub>2</sub> has the above given meanings.

28. Process for the production of compounds of formula XVI, characterised by introducing the mesylate group or tosylate group or the like into a compound of formula XV




by adding mesylate chloride (the mesylate group may be replaced by a corresponding tosylate group or the like) in the presence of triethylamine (Et<sub>3</sub>N) in an inert solvent, e.g. dichloromethane obtaining a compound of formula XVI



wherein both protecting groups TBDMS may be replaced by TES protecting groups or the like and R<sub>2</sub> has the above given meaning.


29. Compounds of formula XVII



wherein the TBDMS protecting group may be replaced by a TES protecting group or the like and R2 has the above given meanings.

30. Process for the production of compounds of formula XVII, characterised by treating the obtained compound of formula XVI with an organic acid in an inert solvent, more precisely with pyridinium p-toluenesulfonate or camphor sulfonic acid in absolute ethanol, hydrolysing the silyl protecting, e.g. the one TBDMS group and obtaining a compound of formula XVII.

31. A new compound of formula 2



32. A method of treatment of a warm-blooded animal suffering from a cancer disease and that is in need of such treatment, comprising administering a compound of the formula 9 wherein R2 is an unsubstituted or substituted aryl radical or a pharmaceutically acceptable salt thereof, according to claim 9 to said warm-blooded animal in an amount that is sufficient for said treatment.

33. A pharmaceutical composition that is suitable for administration to a warm-blooded animal for the treatment of a cancer disease, comprising an amount of an active ingredient of the formula 9 wherein R2 is an unsubstituted or substituted aryl radical according to claim 9, which is effective for the treatment of said cancer disease, together with at least one pharmaceutically acceptable carrier.

34. Use of a compound of formula 8 for preparing a compound of formula 9 for medical treatment.




Fig. 1




Fig. 2



- 54 -




Fig. 3




Fig. 4

- 55 -




Fig. 5

- 56 -




Fig. 6

**This Page is Inserted by IFW Indexing and Scanning  
Operations and is not part of the Official Record**

**BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ **BLACK BORDERS**
- ☐ **IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**
- ☐ **FADED TEXT OR DRAWING**
- ☐ **BLURRED OR ILLEGIBLE TEXT OR DRAWING**
- ☐ **SKEWED/SLANTED IMAGES**
- ☐ **COLOR OR BLACK AND WHITE PHOTOGRAPHS**
- ☐ **GRAY SCALE DOCUMENTS**
- ☐ **LINES OR MARKS ON ORIGINAL DOCUMENT**
- ☐ **REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**
- ☐ **OTHER:** \_\_\_\_\_

**IMAGES ARE BEST AVAILABLE COPY.**

**As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.**